TITLE

Mass biological profiling of cns tumours: Is it possible in india?

AUTHOR(S)
Ray, A.; Buffet, E.; Rutka, J. T.; Hawkins, C.
PUB. DATE
July 2007
SOURCE
Journal of Pediatric Neurosciences;Jul-Dec2007, Vol. 2 Issue 2, p102
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
INTRODUCTION: Biological profiling of tumours to predict outcome is gaining increasing popularity in the western world. The paucity of equipment and the prohibitive costs have meant that such profiling has not been universally popular especially in the developing world. This paper tries to introduce the concept of 'biological profiling' using available equipment at minimal extra cost using medulloblastoma as an illustrative case. EXPERIMENTAL DESIGN: Clinical presentation and survival information were obtained for patients who had undergone surgery for MB at the Hospital for Sick Children between 1985 and 2001. A tissue microarray was constructed from their tumour samples. The arrays were assayed for immunohistochemical expression of MYC, p53, PDGFRα, ErbB2, MIB-1 and TrkC and for apoptosis (TUNEL). Both univariable and multivariable analyses were conducted to characterize the association between survival and both clinical and biological markers. For the strongest predictors of survival a weighted predictive score was calculated based on their hazard ratios (HR). The sum of these scores was then used to give an overall prediction of survival using a nomogram. RESULTS: The four strongest predictors of survival in the final multivariable model were the presence of metastatic disease at presentation (HR 2.02, P=0.01), and p53 (HR 2.29, P=0.02), TrkC (HR 0.65, P=0.14) and ErbB2 (HR 1.51, P=0.21) immunopositivity. A linear prognostic index was derived, with coefficients equal to the logarithm of these hazard ratios. The 5-year survival rate for patients at the 10th, 50th and 90th percentiles of the score distribution were respectively 80.0%, 71.0%, and 35.7% with radiation therapy, and 70.5%, 58.5%, and 20.0% without radiation therapy. CONCLUSIONS: In this study, we demonstrate an approach to combining both clinical and biological markers to quantify risk in MB patients. This provides further prognostic information than can be obtained when either clinical factors or biological markers are studied separately, and establishes a framework for comparing prognostic markers in future clinical studies.
ACCESSION #
27450647

 

Related Articles

  • Evaluation of osteopontin as a potential biomarker for central nervous system embryonal tumors. Han, Yi-Peng; Ma, Chen-Kai; Wang, Shen-Qi; Enomoto, Atsushi; Zhao, Yang; Takahashi, Masahide; Ma, Jie // Journal of Neuro-Oncology;Sep2014, Vol. 119 Issue 2, p343 

    Osteopontin (OPN) is a protein linked to tumor growth, progression and metastasis of cancers. However, its role in the progression of central nervous system (CNS) embryonal tumors such as atypical teratoid/rhabdoid tumor (AT/RT), medulloblastoma (MB) and primitive neuroepithelial tumors (PNET)...

  • FABP4 is a candidate marker of cerebellar liponeurocytomas. Anghileri, Elena; Eoli, Marica; Paterra, Rosina; Ferroli, Paolo; Pollo, Bianca; Cuccarini, Valeria; Maderna, Emanuela; Tringali, Giovanni; Saini, Marco; Salsano, Ettore; Finocchiaro, Gaetano // Journal of Neuro-Oncology;Jul2012, Vol. 108 Issue 3, p513 

    Cerebellar liponeurocytoma (cLPN) is a very rare central nervous system (CNS) tumour recently recognized as a clinical and pathological entity distinct from medulloblastoma (MB), and included in the WHO classification of CNS tumours under the heading 'glioneuronal tumours'. cLPN typically...

  • Embryonal tumor with multilayered rosettes (ETMR): signed, sealed, delivered ... Wesseling, Pieter // Acta Neuropathologica;Aug2014, Vol. 128 Issue 2, p305 

    An introduction is presented in which the editor discusses various reports within the issue on topics including the primitive neuroectodermal tumor (PNET) of central nervous system (CNS), tumor associated amplicon, and ependymoblastomas.

  • Medulloblastoma: a potpourri of distinct entities. Pfister, Stefan // Acta Neuropathologica;Apr2012, Vol. 123 Issue 4, p463 

    An introduction is presented in which the author discusses various reports within the issue on topics including the classification of World Health Organization (WHO) to central nervous system (CNS) tumors, medulloblastoma gene expression, and sonic hedgehog (SHH)-driven medulloblastoma.

  • Primary CNS Lymphoma in the Immunocompetent: A study of 24 cases. Agarwal, Pankaj; R., Rithesh; Singhal, B. S.; Smruti, B. K. // Annals of Indian Academy of Neurology;Nov2008 Supplement, Vol. 11, pS158 

    Primary central nervous system lymphoma (PCNSL) is a rare form of extranodal non-Hodgkins lymphoma, constituting around 1 % of all intracranial tumors. In the last few decades, the incidence of PCNSL has increased several-fold. 24 immunocompetent patients with PCNSL admitted in our institution...

  • Solid Tumours. Valteau, D.; Kalifa, C.; Grill, J.; Benhamou, E.; Hartmann, O.; Dallorso, S.; Rivabella, L.; Cefalo, G.; Milanaccio, C.; Porta, F.; Morreale, G.; Cappelli, B.; Garre, M.L.; Galaron, P.; Calvo, C.; Fernandez-Teijeiro, A.; Couselo, M.; Vivanco, J.L.; Cela, M.E. // Bone Marrow Transplantation;11/1/2002 Supplement, Vol. 30 Issue 9, pS31 

    Bone Marrow Transplantation (2002) 30, S31–S34. doi:10.1038/sj.bmt.1703746

  • Stratification of medulloblastoma on the basis of histopathological grading. Giangaspero, Felice; Wellek, Stefan; Masuoka, Jun; Gessi, Marco; Kleihues, Paul; Ohgaki, Hiroko // Acta Neuropathologica;Jul2006, Vol. 112 Issue 1, p5 

    Medulloblastoma (WHO grade IV) is an embryonal tumour of the cerebellum and the most common malignant central nervous system tumour in children. Despite significant advances in treatment, 5-year survival rates are still less than 70%, suggesting the presence of subgroups with different response...

  • Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. Schwalbe, Ed. C.; Hayden, James T.; Rogers, Hazel A.; Miller, Suzanne; Lindsey, Janet C.; Hill, Rebecca M.; Nicholson, Sarah-Leigh; Kilday, John-Paul; Adamowicz-Brice, Martyna; Storer, Lisa; Jacques, Thomas S.; Robson, Keith; Lowe, Jim; Williamson, Daniel; Grundy, Richard G.; Bailey, Simon; Clifford, Steven C. // Acta Neuropathologica;Dec2013, Vol. 126 Issue 6, p943 

    The article presents a study which demonstrates the utility of DNA methylation profiling to show the distinction of pediatric brain tumour types including medulloblastomas, gliomas and ependymomas. The researchers have assessed the molecular and clinical characteristics of the central nervous...

  • The clinical experience of medulloblastoma treatment and the significance of time sequence for development of leptomeningeal metastasis. Po-Chuan Hsieh; Chieh-Tsai Wu; Kuang-Lin Lin; Tang-Her Jaing; Chen-Kan Tseng; Tai-Ngar Lui; Shih-Ming Jung // Child's Nervous System;Dec2008, Vol. 24 Issue 12, p1463 

    Among patients with medulloblastoma, an unrare aggressive central nervous system (CNS) tumor found mostly in the posterior fossa, drop metastasis from primary location to anatomically lower sites including whole spinal cord is known as a potential way for tumor to spread. There were already lots...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics